Jazz Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: JAZZHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Jazz Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Jazz Pharmaceuticals generated $415.7 million of operating cash flow and spent $18.1 million on capital expenditures. That left free cash flow of $397.6 million, a free-cash-flow margin of 32.9% of revenue. Free cash flow was up 423.8% from the prior year's $75.9 million.
Summary generated from market data by MetaCap's automated system. Methodology
Jazz Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 192.80M | 293.10M | 203.45M | 251.41M | -718.50M | -92.50M | 191.12M | 215.06M | 168.57M | -14.62M | 94.15M | 146.82M |
| Net Income growth (YoY) | — | — | +6.45% | +16.91% | -526.24% | — | +102.98% | +46.48% | +61.40% | -121.06% | — | — |
| Depreciation & Amortization | 9.10M | 9.10M | 9.43M | 9.91M | 11.90M | 10.40M | 9.51M | 7.78M | 7.81M | 7.65M | 7.65M | 7.67M |
| Stock-Based Compensation | 73.30M | 74.50M | 70.85M | 88.08M | 64.50M | 67.70M | 70.19M | 59.76M | 56.65M | 61.44M | 52.94M | 56.12M |
| Change in Working Capital | -65.20M | -41.60M | -33.40M | 87.46M | -116.90M | 93.80M | -14.05M | -27.47M | -29.93M | 48.74M | -121.75M | -33.94M |
| Operating Cash Flow | 415.70M | 408.20M | 362.52M | 474.65M | 88.80M | 429.80M | 398.58M | 398.75M | 331.35M | 267.23M | 167.34M | 307.19M |
| Capital Expenditures | -18.10M | -19.70M | -16.73M | -15.22M | -12.90M | -13.90M | -13.29M | -10.79M | -7.09M | -6.90M | -10.10M | -4.30M |
| Investing Cash Flow | 354.90M | 123.10M | -372.16M | -327.75M | -641.00M | -169.00M | -193.29M | 214.09M | -257.09M | -271.90M | 101.80M | -174.30M |
| Share Repurchases | — | — | 0 | -23.00K | — | — | 0 | -150.00M | — | — | -99.80M | -74.37M |
| Financing Cash Flow | -994.50M | -78.50M | 75.44M | -10.92M | -124.40M | -813.50M | -8.28M | 246.43M | -161.09M | -56.55M | -100.31M | -78.49M |
| Net Change in Cash | -224.50M | 452.40M | 65.83M | 136.21M | -672.00M | -551.00M | 194.73M | 862.33M | -87.58M | -62.92M | 170.62M | 53.39M |
| Free Cash Flow | 397.60M | 388.50M | 345.79M | 459.43M | 75.90M | 415.90M | 385.29M | 387.96M | 324.26M | 260.32M | 157.24M | 302.90M |
This table shows 12 quarterly periods of Jazz Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow JAZZ's reporting calendar. What is a cash flow statement?